
Roche’s meets endpoints in relapsing multiple sclerosis
In patients with relapsing-remitting multiple sclerosis (RRMS), fenebrutinib significantly reduced the total number of new gadolinium-enhancing...

Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

Neogap Therapeutics A/S partners with Cellerys AG
Stockholm based Neogap Therapeutics AB has partnered with Zurich-based Cellerys AG to provide its EpiTCer® platform within Celleris upcoming...

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

Insempra and Axxence launch alpha-ionone
Insempra GmbH has launched its first functional ingredient, a biotechnologically produced, 100% natural alpha-Ionone flavour and fragrance ingredient...

Bayer AG is joining forces with Acuitas Therapeutics, Inc
Following the opening of an cell and gene therapy centre in the US, German Bayer AG opts for joining forces with Acuitas Therapeutics, Inc., a ...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...